Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMRT with or without cisplatin for stage II nasopharyngeal carcinoma
NCT02610010Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2015
- Primary completion
- Nov 2022
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Primary endpoint: Overall Survival at 2 years. Status: unknown.
02
Drugs
cisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02610010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02610010.